Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model

Turetschek, Karl; Roberts, Timothy P.L.; Floyd, Eugenia; Preda, Adrian; Novikov, Viktor; Shames, David M.; Carter, Wayne O.; Brasch, Robert C.

doi:10.1002/jmri.1126

Cited by 75 publications

(52 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, several papers have already shown discrepancies between MRI and mean vessel density data. Turetschek et al have reported no statistically significant correlation between mean vessel density and fPV measured with Gd-DTPA-albumin or other contrast agents in a chemically induced experimental model of breast cancer (9,19,20). Fractional plasma volume determined using Gd-DTPA-albumin (21) or ultrasmall superparamagnetic iron oxide particles (22) was not found to be different in tumors treated with an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases PTK787/ZK 222584, despite a significant decrease in mean vessel density detected in treated tumors.…”

Section: Discussionmentioning

confidence: 99%

Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma

Marzola

Degrassi

Calderan

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To compare two dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) techniques in terms of their ability in assessing the early antiangiogenic effect of SU11248, a novel selective multitargeted tyrosine kinase inhibitor, that exhibits direct antitumor and antiangiogenic activity via inhibition of the receptor tyrosine kinases platelet-derived growth factor receptor, vascular endothelial growth factor receptor, KIT, and FLT3. Experimental Design: A s.c. tumor model of HT29 human colon carcinoma in athymic mice was used. Two DCE-MRI techniques were used based, respectively, on macromolecular [Gddiethylenetriaminepentaacetic acid (DTPA)-albumin] and low molecular weight (Gd-DTPA) contrast agents. The first technique provided a quantitative measurement of transendothelial permeability and fractional plasma volume, accepted surrogate markers of tumor angiogenesis. With the second technique, we quantified the initial area under the concentration-time curve, which gives information related to tumor perfusion and vascular permeability. Experiments were done before and 24 hours after a single dose administration of SU11248. Results:The early antiangiogenic effect of SU11248 was detected by DCE-MRI with macromolecular contrast agent as a 42% decrease in vascular permeability measured in the tumor rim. The effect was also detected by DCE-MRI done with Gd-DTPA as a 31% decrease in the initial area under the concentration-time curve. Histologic slices showed a statistically significant difference in mean vessel density between the treated and control groups. Conclusions: The early antiangiogenic activity of SU11248 was detected in vivo by DCE-MRI techniques using either macromolecular or low molecular weight contrast agents. Because DCE-MRI techniques with low molecular weight contrast agents can be used in clinical studies, these results could be relevant for the design of clinical trials based on new paradigms.

show abstract

Section: Discussionmentioning

confidence: 99%

Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma

Marzola

Degrassi

Calderan

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…The addition of chemical agents that change the MR signal intensity near these abnormalities may also be used to enhance signal differences and to further highlight the abnormality. Specifically, paramagnetic metal cations such as chelated gadolinium or dysprosium, or superparamagnetic nanoparticles (Moore et al 1997Weissleder et al 1997a;Turetschek et al 2001), can be used as compartmental, targeted, or smart probes with this technique (see below). The development of novel contrast agents is an active area in both clinical and basic research.…”

Section: Magnetic Resonance Imagingmentioning

confidence: 99%

Molecular imaging in living subjects: seeing fundamental biological processes in a new light

Massoud¹,

Gambhir²

2003

Genes Dev.

2,031

1,738

View full text Add to dashboard Cite

“…Next, we demonstrate the preclinical potential of our ZESSPIONs as positive contrast agent for MR imaging (49,50) in an animal model. We used a MRI scanner to image mice injected with ZES-SPIONs at a concentration of 0.2 mmol [Fe]/kg, comparable to the concentrations of GBCAs (∼0.1-0.25 mmol [metal]/kg) administered in the clinic.…”

mentioning

confidence: 96%

Exceedingly small iron oxide nanoparticles as positive MRI contrast agents

Bruns

Kaul

et al. 2017

Proc. Natl. Acad. Sci. U.S.A.

413

322

View full text Add to dashboard Cite

Medical imaging is routine in the diagnosis and staging of a wide range of medical conditions. In particular, magnetic resonance imaging (MRI) is critical for visualizing soft tissue and organs, with over 60 million MRI procedures performed each year worldwide. About one-third of these procedures are contrast-enhanced MRI, and gadolinium-based contrast agents (GBCAs) are the mainstream MRI contrast agents used in the clinic. GBCAs have shown efficacy and are safe to use with most patients; however, some GBCAs have a small risk of adverse effects, including nephrogenic systemic fibrosis (NSF), the untreatable condition recently linked to gadolinium (Gd) exposure during MRI with contrast. In addition, Gd deposition in the human brain has been reported following contrast, and this is now under investigation by the US Food and Drug Administration (FDA). To address a perceived need for a Gdfree contrast agent with pharmacokinetic and imaging properties comparable to GBCAs, we have designed and developed zwitterioncoated exceedingly small superparamagnetic iron oxide nanoparticles (ZES-SPIONs) consisting of ∼3-nm inorganic cores and ∼1-nm ultrathin hydrophilic shell. These ZES-SPIONs are free of Gd and show a high T 1 contrast power. We demonstrate the potential of ZES-SPIONs in preclinical MRI and magnetic resonance angiography. exceedingly small iron oxide nanoparticles | renal clearance | gadoliniumfree positive MR contrast agent | preclinical magnetic resonance imaging M RI signal arises from the excitation of low-energy nuclear spins, which are formed in a permanent magnetic field, by applying radiofrequency pulses followed by the measurement of the spin relaxation processes (i.e

show abstract

Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model

Cited by 75 publications

References 22 publications

Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma

Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma

Molecular imaging in living subjects: seeing fundamental biological processes in a new light

Exceedingly small iron oxide nanoparticles as positive MRI contrast agents

Contact Info

Product

Resources

About